TYK2 Inhibition: Evolving Options in Psoriasis Care - Episode 9

Other Emerging TYK2 Inhibitors in Psoriasis

Published on: December 19, 2025

Christopher G. Bunick, MD, PhD, April W. Armstrong, MD, MPH

Panelists discuss the questions below in this video. ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?

EP. 1: Cytokine Pathways and Their Impact on Plaque Psoriasis

EP. 2: Current Standard of Care and Treatment Options in Psoriasis

EP. 3: Role of Mechanisms of Action in Treatment Decisions and Personalized Care in Psorias

EP. 4: Challenges with Current Psoriasis Therapies

EP. 5: Therapeutic Potential of TYK2 Inhibition in Psoriasis

EP. 6: Selectivity of TYK2 Inhibition in Psoriasis

EP. 7: Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis

EP. 8: Efficacy and Safety of Zasocitinib in Psoriasis and the Ideal Candidates for TYK2 Inhibitors

Now Viewing

EP. 9: Other Emerging TYK2 Inhibitors in Psoriasis

Panelists discuss the questions below in this video.
ESK-001, another highly selective TYK2 inhibitor, has advanced into phase 3 trials in plaque psoriasis. How does its mechanism of action and emerging phase 2 data compare with deucravacitinib and zasocitinib, and what features might distinguish it within the TYK2 inhibitor class?